DE4403487A1 - Transdermal therapeutic system for admin. of, e.g. Ketoprofen or oestradiol - Google Patents

Transdermal therapeutic system for admin. of, e.g. Ketoprofen or oestradiol

Info

Publication number
DE4403487A1
DE4403487A1 DE19944403487 DE4403487A DE4403487A1 DE 4403487 A1 DE4403487 A1 DE 4403487A1 DE 19944403487 DE19944403487 DE 19944403487 DE 4403487 A DE4403487 A DE 4403487A DE 4403487 A1 DE4403487 A1 DE 4403487A1
Authority
DE
Germany
Prior art keywords
transdermal therapeutic
therapeutic systems
systems according
drug
copolymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
DE19944403487
Other languages
German (de)
Other versions
DE4403487C2 (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LTS Lohmann Therapie Systeme AG
Original Assignee
Labtec GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Labtec GmbH filed Critical Labtec GmbH
Priority to DE19944403487 priority Critical patent/DE4403487C2/en
Publication of DE4403487A1 publication Critical patent/DE4403487A1/en
Application granted granted Critical
Publication of DE4403487C2 publication Critical patent/DE4403487C2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/22—Lipids, fatty acids, e.g. prostaglandins, oils, fats, waxes
    • A61L2300/222—Steroids, e.g. corticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A61L2300/408—Virucides, spermicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Materials Engineering (AREA)
  • Medicinal Preparation (AREA)
  • Laminated Bodies (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Transdermal therapeutic system, for use with humans or animals and prepd. by a hot melt process, comprises a carrier material, a protective foil which is removed prior to use, and one or more medicaments incorporated into an acrylate copolymer matrix which is crosslinked using UV irradiation.

Description

Transdermale therapeutische Systeme (TTS) sind ein- oder mehrschichtig aufge­ baute wirkstoffhaltige, medizinische Pflaster, die auf der Haut fixiert und die ihre Wirkstoffe perkutan über einen längeren Zeitraum kontinuierlich abgeben. Es handelt sich um neuere Arzneiformen, die für bestimmte Wirksubstanzen besser geeignet sind, als orale Arzneiformen, wie z. B. Tabletten.Transdermal therapeutic systems (TTS) have one or more layers built medicinal plasters containing active ingredients, which are fixed on the skin and which continuously release their active ingredients percutaneously over a longer period of time. These are newer dosage forms that are used for certain active substances are more suitable than oral dosage forms, such as. B. tablets.

TTS werden hergestellt nach dem sog. Lösungsmittel-Beschichtungsverfahren, bei dem große Mengen an Lösungsmitteln benötigt und anschließend mit hohen Kosten zurückgewonnen werden. Bekannt ist auch das sog. hot-melt-Verfahren bzw. Heißschmelzverfahren ohne Verwendung von Lösungsmitteln. Hierbei wird die Herstellung durch Anwendung von Wärme über einen Schmelzprozeß des Polymers ermöglicht.TTS are manufactured using the so-called solvent coating process, where large amounts of solvents are required and then high Costs can be recovered. The so-called hot-melt process is also known or hot melt process without the use of solvents. Here is the manufacture by applying heat through a melting process of the polymer.

Die bislang zu medizinischen Zwecken eingesetzten Hotmelt-Polymere basieren weitgehend auf Kautschuk-ähnlichen Produkten (DE 42 32 472, DE 37 43 946), die jedoch verstärkt zu "kaltem Fluß" neigen (nach Lagerung ein Austreten der Wirkstoff-Polymermasse mit der Gefahr des Verklebens in der Verpackung) und bei denen die Wirkstoff-Freisetzung im Vergleich zu Acrylat-Polymeren schlechter steuerbar ist.The hot melt polymers previously used for medical purposes are based largely on rubber-like products (DE 42 32 472, DE 37 43 946) However, they tend to have a "cold flow" (after storage, the Active ingredient polymer mass with the risk of sticking in the packaging) and where the drug release compared to acrylate polymers is less controllable.

Bekannt ist auch der Einsatz von UV-vernetzbaren Acrylat-Hotmelt-Klebern für den Einsatz in technischen Bereichen wie z. B. zur Herstellung von Haftetiketten, Autozierleisten und Isolierglasfenstern (US 4814215). Diese Polymere sind jedoch nicht zur Anwendung am Menschen untersucht und somit dafür nicht geeignet. Sie können Hautreizung und lokale toxische Effekte ausüben.The use of UV-crosslinkable acrylate hotmelt adhesives is also known use in technical areas such as B. for the production of adhesive labels, Car trim and insulating glass windows (US 4814215). These are polymers however not tested for human use and therefore not for it suitable. They can cause skin irritation and local toxic effects.

Seit kurzem sind UV-vernetzbare Acrylat Polymere auch für die Herstellung von Artikeln im Hygienebereich (Damenbinden, Bandagen) und chirurgische Pflaster beschrieben worden. Letztere sollen das Nahtmaterial bei Operationswunden ersetzen (DE 42 43 270 und DE 42 22 334).Recently UV-curable acrylate polymers have also been used in manufacturing of articles in the hygiene area (sanitary napkins, bandages) and surgical Patches have been described. The latter are said to add the suture material Replace surgical wounds (DE 42 43 270 and DE 42 22 334).

Schließlich ist bekannt, arzneistoffhaltige Aaylat-Hotmelt-Pflaster herzustellen, bei denen jedoch keine UV-Vernetzung erfolgt (DE 43 10 012). Finally, it is known to produce drug-containing Aaylat hotmelt plasters, in which, however, there is no UV crosslinking (DE 43 10 012).  

Es wurde nun gefunden, daß es möglich ist, arzneistoffhaltige transdermale the­ rapeutische Systeme durch Einsatz von mit UV Bestrahlung vernetzbaren Acrylat-Haftschmelz-Klebstoffen herzustellen, die den medizinischen Anforderungen zur Anwendung am Menschen entsprechen.It has now been found that it is possible to transdermal the drug-containing therapeutic systems through the use of UV radiation Acrylic pressure sensitive hot melt adhesives to manufacture the medical Meet requirements for human use.

Durch Variation der Belichtungszeit mit UV-Licht sind Kohäsions- und Adhä­ sionseigenschaften der Polymer-Wirkstoffgemische einstellbar. Da der Grad der Vernetzung der Polymergruppen in diesen Klebstoffgemischen durch UV- Strahlen induziert wird, ist er für unterschiedliche Polymer-Wirkstoffgemische individuell steuerbar. Damit ist ein neuer Weg für die Herstellung von transdermale therapeutische Systeme auf der hot melt Basis gegeben.By varying the exposure time with UV light, there is cohesion and adhesion sion properties of the polymer-active substance mixtures adjustable. Because the degree of Crosslinking of the polymer groups in these adhesive mixtures by UV Radiation is induced, it is for different polymer-active ingredient mixtures individually controllable. This is a new way of producing given transdermal therapeutic systems on a hot melt basis.

Die vorliegende Erfindung betrifft somit transdermale therapeutische Systeme, welche dadurch gekennzeichnet sind, daß der/die Wirkstoffe in hautfreund­ lichen, medizinisch für die Anwendung am Menschen geeigneten UV-vernetz­ baren Aaylat-Haftschmelzklebstoffen eingearbeitet sind, die nach dem hot­ melt-Verfahren hergestellt werden. Das UV-Licht hat vorzugsweise eine Wellen­ länge von 200-400 nm und die Vernetzung der Acrylatkleber kann einfach und gezielt durch Variation der Belichtungszeiten bis zum Faktor 20 speziell für jede beliebige Wirkstoff-Kleber-Kombination eingestellt werden. Die Temperatur, bei der die Herstellung erfolgt, liegt im Bereich von 100-150° C, vorzugsweise 110- 135° C, und damit unter der sonst üblichen Temperatur bei Herstellung von TTS nach dem hot melt-Verfahren auf der Basis von Kautschuk-ähnlichen Polymeren. Dieses kommt natürlich der Stabilität der eingesetzten Arzneistoffe zugute.The present invention thus relates to transdermal therapeutic systems, which are characterized in that the active ingredient (s) are skin-friendly medical UV network suitable for human use baren Aaylat hotmelt adhesives are incorporated, which after the hot melt process can be produced. The UV light preferably has waves length of 200-400 nm and the crosslinking of the acrylic adhesive can be simple and targeted by varying the exposure times up to a factor of 20 specifically for each any active substance-adhesive combination can be set. The temperature at which is produced is in the range of 100-150 ° C, preferably 110- 135 ° C, and thus below the usual temperature for the production of TTS after the hot melt process based on rubber-like Polymers. This of course comes from the stability of the drugs used benefit.

Die optimale Konzentration eines Wirkstoffes in den erfindungsgemäßen trans­ dermalen therapeutischen Systemen ist von der Art des Wirkstoffes abhängig und muß durch galenische Versuche ermittelt werden. In der Regel wird der Wirkstoff in einer Konzentration von 0,1-30 Gewichtsprozent bezogen auf die fertige Matrix dosiert. Die Dicke der arzneimittelhaltigen Klebstoffschicht beträgt in der Regel 20-400 µm. Die Abgabe des Wirkstoffes erfolgt über eine Fläche, die zwischen 5 und 200 cm² variieren kann.The optimal concentration of an active ingredient in the trans according to the invention dermal therapeutic systems depend on the type of active substance and must be determined by galenic experiments. As a rule, the Active ingredient in a concentration of 0.1-30 percent by weight based on the finished matrix dosed. The thickness of the drug-containing adhesive layer is usually 20-400 µm. The active ingredient is delivered via a Area that can vary between 5 and 200 cm².

Das erfindungsgemäße Pflaster besteht aus einem Trägermaterial (Folien, Vlies­ stoffe, längs-quer-elastisches Gewebe etc.) und einer Schutzfolie, die vor Ge­ brauch des Pflasters entfernt wird. Der Klebstoff-Matrix können ferner System­ stabilisierende und Penetrations-beschleunigende Substanzen zugesetzt werden. The plaster according to the invention consists of a carrier material (foils, fleece fabrics, lengthways-cross-elastic fabric etc.) and a protective film that protects against Ge the plaster is removed. The adhesive matrix can also system stabilizing and penetration-accelerating substances are added.  

Wirkstoffe, die sich zur Herstellung der erfindungsgemäßen transdermalen the­ rapeutischen Systeme eignen müssen hitzestabil bis zur Verarbeitungstempera­ tur des Matrix-Polymers sein und können beispielsweise sein: Steroidhormone mit gestagener ( z. B. Norethisteronacetat, Lynestrenol, Desogestrel, Gestoden), estrogener ( z. B. Estradiol, Ethinylestradiol), androgener (z. B. Testosteron) oder anti-androgener (Cyproteronacetat) Wirksamkeit, Kortikoide (z. B. Hydroxycor­ tison, Prednisolon), Antimykotika (z. B. Clotrimazol, Miconazol, Bifonazol, Ke­ toconazol, Econazol ), Antiphiogistika (z. B. Diclofenac-Säure, Diclofenac-Na, Ibuprofen, FIurbiprofen, Ketoprofen, Indometacin), Antiepileptika (z. B. Carba­ mazepin, Phenytoin ), Analgetika ( z. B. Fentanyl, Morphin, Pentazozin, Bu­ prenorphin) Psychopharmaka ( Diazepam, Haloperidol), Betablocker (z. B. Mepindolol, Propranolol ), Calcium-Antagonisten ( z.B Nifedipin) sowie Caro­ tinoide.Active ingredients that are used in the production of the transdermal the therapeutic systems must be heat-stable up to the processing temperature structure of the matrix polymer and can be, for example: steroid hormones with progestogen (e.g. norethisterone acetate, lynestrenol, desogestrel, gestoden), estrogenic (e.g. estradiol, ethinyl estradiol), androgenic (e.g. testosterone) or anti-androgenic (cyproterone acetate) effectiveness, corticoids (e.g. Hydroxycor tison, prednisolone), antifungals (e.g. clotrimazole, miconazole, bifonazole, Ke toconazole, econazole), antiphiogistics (e.g. diclofenac acid, diclofenac Na, Ibuprofen, FIurbiprofen, Ketoprofen, Indometacin), antiepileptics (e.g. Carba mazepin, phenytoin), analgesics (e.g. fentanyl, morphine, pentazozin, Bu prenorphin) psychotropic drugs (diazepam, haloperidol), beta blockers (e.g. Mepindolol, propranolol), calcium antagonists (e.g. nifedipine) and caro tinoids.

Die nachfolgenden Beispiele dienen zur näheren Erläuterung der Erfindung:The following examples serve to explain the invention in more detail:

Beispiel 1:Example 1:

180 g Ecocure UV®, Fa. Ebnöther werden ca. 5 min. bei 110°C in einem Duplex- Doppel-Z-Kneter bearbeitet. Nach Zugabe von 20 g Ketoprofen wird das Ge­ misch 45 min. homogenisiert. Die Wirkstoff-Acrylatpolymermasse wird in den Tank (Temperatur 120°C) einer Labor-Streichanlage, Fa. Acumeter, überführt und mit einem Flächengewicht von ca. 60 g/m² auf eine 23 µm starke Polyester­ folie (Fa. Du Pont, Typ Melinex) aufgetragen.180 g Ecocure UV®, from Ebnöther, are approx. 5 min. at 110 ° C in a duplex Machined double Z kneader. After adding 20 g of ketoprofen, the Ge mix 45 min. homogenized. The active ingredient acrylic polymer mass is in the Tank (temperature 120 ° C) of a laboratory coating system, Acumeter, transferred and with a basis weight of approx. 60 g / m² on a 23 µm thick polyester foil (Du Pont, type Melinex) applied.

Etwa 60 cm lange Laminatstücke werden dann 1 mal in einer UV-Belichtungsan­ lage der Fa. Eltosch, Modell F 200 (80W/cm) belichtet. Die Laminate durchlau­ fen die Belichtungsanlage mit einer Geschwindigkeit von 12,3 m/min.About 60 cm long pieces of laminate are then applied once in a UV exposure exposed by Eltosch, model F 200 (80W / cm). The laminates are translucent open the exposure system at a speed of 12.3 m / min.

Anschließend werden die Laminate mit einseitig silikonisiertem Papier (Fa 4P, Typ HV 67473) durch Auflegen und Glattstreichen kaschiert. Die so erhaltenen Laminate werden mit einer Stanzvorrichtung in Einzelpflaster Größe: 40 cm² und 100 cm² geteilt und in aluminierte Beutel verpackt.Then the laminates are coated with siliconized paper on one side (Fa 4P, Type HV 67473) covered by laying and smoothing. The so obtained Laminates are made with a punching device in single plaster size: 40 cm² and 100 cm² divided and packed in aluminized bags.

Beispiel 2:Example 2:

180 g Ecocure UV® , Fa. Ebnöther werden ca. 5 min. bei 110°C in einem Duplex- Doppel-Z-Kneter bearbeitet. Nach Zugabe von 20 g Norethisteron-acetat wird das Gemisch 30 min. homogenisiert. Die Wirkstoff-Acrylatpolymermasse wird in den Tank (Temperatur 120°C) einer Labor-Streichanlage, Fa. Acumeter, über­ führt und mit einem Flächengewicht von ca. 60 g/m² auf eine 23 µm starke Po­ lyesterfohe (Fa. Du Pont, Typ Melinex) aufgetragen.180 g Ecocure UV®, from Ebnöther, are approx. 5 min. at 110 ° C in a duplex Machined double Z kneader. After adding 20 g of norethisterone acetate the mixture 30 min. homogenized. The active ingredient acrylic polymer mass is into the tank (temperature 120 ° C) of a laboratory coating system from Acumeter leads and with a basis weight of approx. 60 g / m² to a 23 µm thick bottom lyesterfohe (Du Pont, Melinex type) applied.

Etwa 60 cm lange Laminatstücke werden dann 9 mal in einer UV-Belichtungsan­ lage der Fa. Eltosch, Modell F 200 (80W/cm) belichtet. Die Laminate durchlau­ fen die Belichtungsanlage mit einer Geschwindigkeit von 12,3 m/min. Anschließend wurde wie in Beispiel 1 verfahren. About 60 cm long pieces of laminate are then 9 times in a UV exposure exposed by Eltosch, model F 200 (80W / cm). The laminates are translucent open the exposure system at a speed of 12.3 m / min. The procedure was then as in Example 1.  

Beispiel 3:Example 3:

180 g Ecocure UV® , Fa. Ebnöther werden ca. 5 min. bei 110°C in einem Duplex- Doppel-Z-Kneter bearbeitet. Nach Zugabe von 20 g Indometacin wird das Ge­ misch 40 min. homogenisiert. Die Wirkstoff-Acrylatpolymermasse wird in den Tank (Temperatur 120°C) einer Labor-Streichanlage, Fa. Acumeter, überführt und mit einem Flächengewicht von ca. 60 g/m² auf eine 23 µm starke Polyester­ folie (Fa. Du Pont, Typ Melinex) aufgetragen.180 g Ecocure UV®, from Ebnöther, are approx. 5 min. at 110 ° C in a duplex Machined double Z kneader. After adding 20 g of indomethacin, the Ge mixed 40 min. homogenized. The active ingredient acrylic polymer mass is in the Tank (temperature 120 ° C) of a laboratory coating system, Acumeter, transferred and with a basis weight of approx. 60 g / m² on a 23 µm thick polyester foil (Du Pont, type Melinex) applied.

Etwa 60 cm lange Laminatstücke werden dann 3 mal in einer UV-Belichtungsan­ lage der Fa. Eltosch, Modell F 200 (80W/cm) belichtet. Die Laminate durchliefen die Belichtungsanlage mit einer Geschwindigkeit von 12,3 m/min. Anschließend wurde wie in Beispiel 1 verfahren.About 60 cm long pieces of laminate are then 3 times in a UV exposure exposed by Eltosch, model F 200 (80W / cm). The laminates went through the exposure system at a speed of 12.3 m / min. The procedure was then as in Example 1.

Beispiel 4:Example 4:

160 g Ecocure UV® , Fa. Ebnöther werden ca. 5 min. bei 110°C in einem Duplex- Doppel-Z-Kneter bearbeitet. Nach Zugabe von 40 g Econazol wird das Gemisch 30 min. homogenisiert. Die Wirkstoff-Acrylatpolymermasse wird in den Tank (Temperatur 120°C) einer Labor-Streichanlage, Fa. Acumeter, überführt und mit einem Flächengewicht von ca. 60 g/m² auf eine 23 µm starke Polyesterfolie (Fa. Du Pont, Typ Melinex) aufgetragen.160 g Ecocure UV®, from Ebnöther, are approx. 5 min. at 110 ° C in a duplex Machined double Z kneader. After adding 40 g of econazole, the mixture 30 min. homogenized. The active ingredient acrylic polymer mass is in the tank (Temperature 120 ° C) of a laboratory coating system, Acumeter, transferred and with a basis weight of approx. 60 g / m² on a 23 μm thick polyester film (from Du Pont, type Melinex).

Etwa 60 cm lange Laminatstücke werden dann 4 mal in einer UV-Belichtungsan­ lage der Fa. Eltosch, Modell F 200 (80W/cm) belichtet. Die Laminate durchliefen die Belichtungsanlage mit einer Geschwindigkeit von 12,0 m/min. Anschließend wurde wie in Beispiel 1 verfahren.About 60 cm long pieces of laminate are then 4 times in a UV exposure exposed by Eltosch, model F 200 (80W / cm). The laminates went through the exposure system at a speed of 12.0 m / min. The procedure was then as in Example 1.

Beispiel 5:Example 5:

150 g Ecocure UV®, Fa. Ebnöther werden ca. 5 min. bei 110°C in einem Duplex- Doppel-Z-Kneter bearbeitet. Nach Zugabe von 50 g Ketoprofen wird das Ge­ misch 45 min. homogenisiert. Die Wirkstoff-Aaylatpolymermasse wird in den Tank (Temperatur 120°C) einer Labor-Streichanlage, Fa. Acumeter, überführt und mit einem Flächengewicht von ca. 40 g/m² auf eine 23 µm starke Polyester­ folie (Fa. Du Pont, Typ Melinex) aufgetragen.150 g Ecocure UV®, Ebnöther, are approx. 5 min. at 110 ° C in a duplex Machined double Z kneader. After adding 50 g of ketoprofen, the Ge mix 45 min. homogenized. The active ingredient polymer polymer mass is in the Tank (temperature 120 ° C) of a laboratory coating system, Acumeter, transferred and with a basis weight of approx. 40 g / m² on a 23 µm thick polyester foil (Du Pont, type Melinex) applied.

Etwa 60 cm lange Laminatstücke werden dann 1 mal in einer UV-Belichtungsan­ lage der Fa. Eltosch, Modell F 200 (80W/cm) belichtet. Die Larninate durchlau­ fen die Belichtungsanlage mit einer Geschwindigkeit von 12,3 m/min. Anschließend wurde wie in Beispiel 1 verfahren.About 60 cm long pieces of laminate are then applied once in a UV exposure exposed by Eltosch, model F 200 (80W / cm). The Larninate transparent open the exposure system at a speed of 12.3 m / min. The procedure was then as in Example 1.

Claims (6)

1. Transdermale therapeutische Systeme zur Anwendung am Menschen oder an Tieren hergestellt nach dem Heißschmelzverfahren, bestehend aus einem Trägermaterial, einer vor Gebrauch zu entfernenden Schutzfolie und einem oder mehreren Arzneistoffen in einer Polymer-Matrix dadurch gekennzeichnet, daß der/die Arzneistoff(e) in ein Aaylat-Copolymer eingearbeitet ist/sind, welches mit UV-Bestrahlung vernetzt wird.1. Transdermal therapeutic systems for use in humans or animals produced by the hot-melt process, consisting of a carrier material, a protective film to be removed before use and one or more drugs in a polymer matrix, characterized in that the drug (s) in anaylate copolymer is / are incorporated, which is crosslinked with UV radiation. 2. Transdermale therapeutische Systeme gem. Anspruch 1, dadurch ge­ kennzeichnet, daß die Polymer Matrix zusätzlich hydriertes Kolophoniumharz oder andere Hilfsstoffe mit gleicher Funktion in einer Menge von 10 - 30 Gewichts-% bezogen auf das Aaylat-Copolymer enthält.2. Transdermal therapeutic systems according to Claim 1, thereby ge indicates that the polymer matrix additionally hydrogenated rosin or other auxiliary substances with the same function in an amount of 10 - 30 Contains% by weight based on the Aaylat copolymer. 3. Transdermale therapeutische Systeme gem. Anspruch 1, dadurch gekenn­ zeichnet, daß zur Herstellung das Acrylat-Copolymer "Ecocure UV N1 EX 79®" der Fa. Ebnöther, Sempach-Station, Schweiz oder ein ähnliches Acrylat- Copolymer eingesetzt wird.3. Transdermal therapeutic systems according to Claim 1, characterized indicates that the acrylate copolymer "Ecocure UV N1 EX 79®" from Ebnöther, Sempach-Station, Switzerland or a similar acrylate Copolymer is used. 4. Transdermale therapeutische Systeme gem. Anspruch 1-3 dadurch gekennzeichnet, daß als Arzneistoff(e) Antimykotika verwendet werden.4. Transdermal therapeutic systems according to Claims 1-3 thereby characterized in that antimycotics are used as the drug (s). 5. Transdermale therapeutische Systeme gem. Anspruch 1-3, dadurch gekennzeichnet, daß als Arzneistoff(e) ein oder mehrere Steroidhormone venwendet werden.5. Transdermal therapeutic systems according to Claims 1-3, thereby characterized in that one or more steroid hormones as the drug (s) be used. 6. Transdermale therapeutische Systeme gem. Anspruch 1-3, dadurch gekennzeichnet, daß als Arzneistoff ein nichtsteroidales Antiphlogistikum verwendet wird.6. Transdermal therapeutic systems according to Claims 1-3, thereby characterized in that a non-steroidal anti-inflammatory drug is used.
DE19944403487 1994-02-04 1994-02-04 Pharmaceutical patches with UV-crosslinkable acrylate copolymers Expired - Fee Related DE4403487C2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE19944403487 DE4403487C2 (en) 1994-02-04 1994-02-04 Pharmaceutical patches with UV-crosslinkable acrylate copolymers

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19944403487 DE4403487C2 (en) 1994-02-04 1994-02-04 Pharmaceutical patches with UV-crosslinkable acrylate copolymers

Publications (2)

Publication Number Publication Date
DE4403487A1 true DE4403487A1 (en) 1995-08-10
DE4403487C2 DE4403487C2 (en) 2003-10-16

Family

ID=6509495

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19944403487 Expired - Fee Related DE4403487C2 (en) 1994-02-04 1994-02-04 Pharmaceutical patches with UV-crosslinkable acrylate copolymers

Country Status (1)

Country Link
DE (1) DE4403487C2 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998029143A1 (en) * 1996-12-27 1998-07-09 Lts Lohmann Therapie-Systeme Gmbh Extremely flexible plaster acting dermally or transdermally, and method for producing same
EP0976397A2 (en) * 1998-07-31 2000-02-02 Beiersdorf Aktiengesellschaft Improved release of ibuprofen from pressure-sensitive hot melt adhesives by the addition of pharmaceutical excipients
DE10032537A1 (en) * 2000-07-05 2002-01-31 Labtec Gmbh Dermal system containing 2- (3-benzophenyl) propionic acid
DE10049225A1 (en) * 2000-09-28 2002-04-11 Labtec Gmbh Dermal therapeutic system comprises diclofenac sodium in an acrylate copolymer matrix on a polyester web
DE10141652A1 (en) * 2001-08-24 2003-03-13 Lohmann Therapie Syst Lts Transdermal therapeutic system based on polyacrylate pressure-sensitive adhesives without functional groups
EP1449526A1 (en) * 2003-02-21 2004-08-25 Schering AG New UV-stable transdermal patch
EP1452173A1 (en) * 2003-02-25 2004-09-01 Schering AG UV-stable transdermal patch
WO2004073696A1 (en) * 2003-02-21 2004-09-02 Schering Ag Uv stable transdermal therapeutic plaster
US8668925B2 (en) 2003-12-12 2014-03-11 Bayer Intellectual Property Gmbh Transdermal delivery of hormones without the need of penetration enhancers
US8962013B2 (en) 2005-05-02 2015-02-24 Bayer Intellectual Property Gmbh Multi-layered transdermal system with triazine UV absorber

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3743946A1 (en) * 1987-09-01 1989-03-09 Lohmann Gmbh & Co Kg DEVICE FOR DELIVERING NITROGLYCERIN TO THE SKIN, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE
DE3743945A1 (en) * 1987-09-01 1989-03-09 Lohmann Gmbh & Co Kg DEVICE FOR DELIVERING SUBSTANCES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE
US4814215A (en) * 1986-11-07 1989-03-21 The B. F. Goodrich Company Adhesive composition, process, and product
DE3817452A1 (en) * 1988-05-21 1989-11-30 Basf Ag MELT-ADHESIVE GLUE ADHESIVE IN THE AIR WITH ULTRAVIOLET RAYS
DE3933460A1 (en) * 1989-10-06 1991-04-18 Lohmann Therapie Syst Lts OSTROGEN-ACTIVE PLASTER
DE3942232A1 (en) * 1989-12-21 1991-06-27 Beiersdorf Ag MELT ADHESIVE ON ACRYLIC BASE
WO1991014461A1 (en) * 1990-03-28 1991-10-03 Smith & Nephew Plc Adhesive compositions
EP0455458A2 (en) * 1990-05-02 1991-11-06 Minnesota Mining And Manufacturing Company Crosslinked pressure-sensitive adhesives tolerant of alcohol-based excipients used in transdermal delivery devices and method of preparing same
DE4020144A1 (en) * 1990-06-25 1992-01-09 Lohmann Therapie Syst Lts Patches for topical or transdermal drug delivery - with adhesive layer contg. polyacrylate adhesive and film former
DE3643987C2 (en) * 1986-12-22 1992-07-23 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg, 5450 Neuwied, De
US5186938A (en) * 1984-07-24 1993-02-16 Key Pharmaceuticals, Inc. Adhesive transdermal dosage layer
DE4222334A1 (en) * 1992-07-08 1994-01-13 Beiersdorf Ag Hot melt pressure sensitive adhesive for medical products
DE4232472A1 (en) * 1992-09-28 1994-03-31 Lohmann Gmbh & Co Kg New melt adhesives which have been cross-linked by irradiation - useful, e.g. in plasters, transdermal therapeutic systems, adhesive tapes, etc.
DE4243270A1 (en) * 1992-12-21 1994-06-23 Lohmann Gmbh & Co Kg Process for crosslinking pressure sensitive adhesives using lasers
DE4310012A1 (en) * 1993-03-27 1994-09-29 Roehm Gmbh Dermal therapeutic system made of a meltable poly (meth) acrylate mixture

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5186938A (en) * 1984-07-24 1993-02-16 Key Pharmaceuticals, Inc. Adhesive transdermal dosage layer
US4814215A (en) * 1986-11-07 1989-03-21 The B. F. Goodrich Company Adhesive composition, process, and product
DE3643987C2 (en) * 1986-12-22 1992-07-23 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg, 5450 Neuwied, De
DE3743945A1 (en) * 1987-09-01 1989-03-09 Lohmann Gmbh & Co Kg DEVICE FOR DELIVERING SUBSTANCES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE
DE3743946A1 (en) * 1987-09-01 1989-03-09 Lohmann Gmbh & Co Kg DEVICE FOR DELIVERING NITROGLYCERIN TO THE SKIN, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE
DE3817452A1 (en) * 1988-05-21 1989-11-30 Basf Ag MELT-ADHESIVE GLUE ADHESIVE IN THE AIR WITH ULTRAVIOLET RAYS
DE3933460A1 (en) * 1989-10-06 1991-04-18 Lohmann Therapie Syst Lts OSTROGEN-ACTIVE PLASTER
DE3942232A1 (en) * 1989-12-21 1991-06-27 Beiersdorf Ag MELT ADHESIVE ON ACRYLIC BASE
WO1991014461A1 (en) * 1990-03-28 1991-10-03 Smith & Nephew Plc Adhesive compositions
EP0455458A2 (en) * 1990-05-02 1991-11-06 Minnesota Mining And Manufacturing Company Crosslinked pressure-sensitive adhesives tolerant of alcohol-based excipients used in transdermal delivery devices and method of preparing same
DE4020144A1 (en) * 1990-06-25 1992-01-09 Lohmann Therapie Syst Lts Patches for topical or transdermal drug delivery - with adhesive layer contg. polyacrylate adhesive and film former
DE4222334A1 (en) * 1992-07-08 1994-01-13 Beiersdorf Ag Hot melt pressure sensitive adhesive for medical products
DE4232472A1 (en) * 1992-09-28 1994-03-31 Lohmann Gmbh & Co Kg New melt adhesives which have been cross-linked by irradiation - useful, e.g. in plasters, transdermal therapeutic systems, adhesive tapes, etc.
DE4243270A1 (en) * 1992-12-21 1994-06-23 Lohmann Gmbh & Co Kg Process for crosslinking pressure sensitive adhesives using lasers
DE4310012A1 (en) * 1993-03-27 1994-09-29 Roehm Gmbh Dermal therapeutic system made of a meltable poly (meth) acrylate mixture

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998029143A1 (en) * 1996-12-27 1998-07-09 Lts Lohmann Therapie-Systeme Gmbh Extremely flexible plaster acting dermally or transdermally, and method for producing same
EP0976397A2 (en) * 1998-07-31 2000-02-02 Beiersdorf Aktiengesellschaft Improved release of ibuprofen from pressure-sensitive hot melt adhesives by the addition of pharmaceutical excipients
EP0976397A3 (en) * 1998-07-31 2002-02-06 Beiersdorf Aktiengesellschaft Improved release of ibuprofen from pressure-sensitive hot melt adhesives by the addition of pharmaceutical excipients
DE10032537A1 (en) * 2000-07-05 2002-01-31 Labtec Gmbh Dermal system containing 2- (3-benzophenyl) propionic acid
DE10049225A1 (en) * 2000-09-28 2002-04-11 Labtec Gmbh Dermal therapeutic system comprises diclofenac sodium in an acrylate copolymer matrix on a polyester web
DE10141652A1 (en) * 2001-08-24 2003-03-13 Lohmann Therapie Syst Lts Transdermal therapeutic system based on polyacrylate pressure-sensitive adhesives without functional groups
DE10141652B4 (en) * 2001-08-24 2011-04-07 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system based on polyacrylate pressure-sensitive adhesives without functional groups and its use
WO2004073696A1 (en) * 2003-02-21 2004-09-02 Schering Ag Uv stable transdermal therapeutic plaster
EA008098B1 (en) * 2003-02-21 2007-02-27 Шеринг Акциенгезельшафт Uv stable transdermal therapeutic plaster
EP1449526A1 (en) * 2003-02-21 2004-08-25 Schering AG New UV-stable transdermal patch
US8486443B2 (en) 2003-02-21 2013-07-16 Bayer Ip Gmbh UV stable transdermal therapeutic plaster with a UV absorbing adhesive layer separated from the drug matrix
HRP20050828B1 (en) * 2003-02-21 2013-10-25 Bayer Intellectual Property Gmbh Uv stable transdermal therapeutic plaster
US9095691B2 (en) 2003-02-21 2015-08-04 Bayer Intellectual Property Gmbh UV stable transdermal therapeutic plaster with a UV absorbing self-adhesive layer separated from the drug matrix
EP1452173A1 (en) * 2003-02-25 2004-09-01 Schering AG UV-stable transdermal patch
US8668925B2 (en) 2003-12-12 2014-03-11 Bayer Intellectual Property Gmbh Transdermal delivery of hormones without the need of penetration enhancers
US9005653B2 (en) 2003-12-12 2015-04-14 Bayer Intellectual Property Gmbh Transdermal delivery of hormones with low concentration of penetration enhancers
US8962013B2 (en) 2005-05-02 2015-02-24 Bayer Intellectual Property Gmbh Multi-layered transdermal system with triazine UV absorber

Also Published As

Publication number Publication date
DE4403487C2 (en) 2003-10-16

Similar Documents

Publication Publication Date Title
DE69617732T2 (en) TRANSDERMAL ESTRADIOL / PROGESTOGEN PLASTER AND THEIR PRODUCTION
DE60017831T2 (en) DERIVED COMPOSITIONS
DE60033426T2 (en) ADHESIVE PREPARATIONS
EP0617972B1 (en) Dermal therapeutic system based on a mixture of fusible polymethacrylates
EP1855660B2 (en) Non-fibrous transdermal therapeutic system and method for its production
DE19728517C2 (en) TTS for the administration of sex steroid hormones and process for its preparation
DE69524614T2 (en) MEDICINAL COMPONENTS, INCLUDING AN N-SUBSTITUTED O-TOLUIDE INDEXIVATIVE AND TRANSDERMALLY ABSORBABLE PREPARATION
EP0464573A1 (en) Plaster high in softening substances
DE69916492T3 (en) PLASTER FOR THE TRANSDERMAL APPLICATION OF VOLATILE, LIQUID ACTIVE SUBSTANCES
DE19500662C2 (en) Plaster containing estradiol and its use
EP1103260A2 (en) Transdermal system for the administration of clonidine
EP0356382A2 (en) Multilayer plaster
EP0697860A1 (en) Transdermal therapeutic system containing estradiol
DE4230588C1 (en) Dexpanthenol-containing plaster for the transdermal application of steroid hormones and process for its production
DE4405898A1 (en) Transdermal therapeutic systems containing sex steroids
EP2111857A1 (en) Transdermal therapeutic system for application of fentanyl or an analogue material thereof
EP1191927B1 (en) Microreservoir system on the basis of polysiloxanes and ambiphilic solvents
EP1100477B1 (en) Patch comprising wool fat or its components and zinc oxide, suitable for the transdermal administration of estradiol
EP1089719B1 (en) Transdermal therapeutic system containing hormones and crystallization inhibitors
DE4403487A1 (en) Transdermal therapeutic system for admin. of, e.g. Ketoprofen or oestradiol
EP1231906B1 (en) Transdermal therapeutic system containing highly volatile active ingredients
JPH066534B2 (en) Transdermal patch
DE10118282A1 (en) Pressure sensitive adhesive based on ethylene-vinyl acetate copolymers and adhesive resins, for medical purposes
DE19642043A1 (en) Transdermal therapeutic system for treating drug dependency
DE10035891A1 (en) Medical pressure sensitive adhesive with a two-phase adhesive matrix made of polyacrylates and polyamine salts

Legal Events

Date Code Title Description
OM8 Search report available as to paragraph 43 lit. 1 sentence 1 patent law
8127 New person/name/address of the applicant

Owner name: LTS LOHMANN THERAPIE-SYSTEME GMBH, 56567 NEUWIED,

8127 New person/name/address of the applicant

Owner name: LTS LOHMANN THERAPIE-SYSTEME AG, 56626 ANDERNACH,

8110 Request for examination paragraph 44
8304 Grant after examination procedure
8364 No opposition during term of opposition
R119 Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee

Effective date: 20120901